Insight Molecular Diagnostics Inc.

NASDAQ:IMDX

Medical - Diagnostics & Research

Healthcare
$1.59 +2.44%

+$0.13 today

Market cap
$52.08M
Beta
1.79
P/E (TTM)
-3.9
EPS (TTM)
-$1.39
52W Low $2.33High $8.51

Volume 0.64M

Average 0.38M

IMDX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Insight Molecular Diagnostics Inc.NASDAQ: IMDX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $4.29M (cash outflow) fell 35.7% year over year, behind the -17.8% change in trailing-twelve-month net income. Sequentially, it fell 81.3% from the prior quarter. Over 3 fiscal years it compounded at -11.7% a year.

Context

  • Net income amounted to 1238.5% of revenue in FY2025, down 1986.5 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of -$23.38M (-53.5%) for the fiscal year ending Dec 2026, a slowdown from the -17.2% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.29M-81.3% QoQ
Last fiscal yearDec 2025
-$50.22M-17.2% YoY
LTMMar 2026
-$47.84M-17.8% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-35.7%-3.9%+31.8 pp
1 year-17.2%-53.5%-36.2 pp
3-year CAGR-11.7%-24.1%-12.4 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(50.22M) USD
Year-over-year change
+17.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How IMDX compares with its peers on the latest reported figures

  • IMDX's LTM Mar 2026 net income of $47.84M is the 9th largest of the 10 companies compared; the peer median is $77.6M.
  • Its year-over-year change of -17.8% is the 6th highest of 10, against a peer median of -11.4%.
  • Net income amounts to 2454.6% of revenue for IMDX, versus a peer median of 327.3%.
IMDX Competitors Peer median
Net Income for IMDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$282.61M +66241.3%+67.6%9554.2%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$123.33M +55.2%-13.9%356.9%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$103.8M +0.5%-6.4%297.8%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$77.8M -39.1%-4.8%465.3%
IVVDInvivyd, Inc.LTM Mar 2026$77.6M -45.6%-39.9%138.9%
PEPGPepGen Inc.LTM Mar 2026$77.22M -24.4%+9.1%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$68.36M +31.7%+2.6%3832.0%
OABIOmniAb, Inc.LTM Mar 2026$54.29M -11.4%+42.6%187.8%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$47.84M -17.8%-11.7%2454.6%
CDXSCodexis, Inc.LTM Mar 2026$31.99M -57.0%+9.4%41.0%
Peer median (excluding IMDX) $77.6M-11.4%+2.6%327.3%

Competitors are the stored peer set for IMDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(64.1M)(72.9M)(27.78M)(60.66M)(50.22M)
Depreciation & Amortization4.21M5.22M1.68M1.56M2.2M
Deferred Income Tax(9.26M)0000
Stock-Based Compensation6.84M10.04M6.57M1.91M2.22M
Change in Working Capital149K(1.94M)(3.97M)(1.32M)2.73M
Accounts Receivables(1.23M)(575K)109K(1.13M)485K
Inventory000(410K)(36K)
Accounts Payables(1.35M)297K(4.76M)967K2.65M
Other Working Capital2.73M(1.66M)677K(749K)(368K)
Other Non-Cash Items26.22M14.01M174K37.79M20.9M
Operating Cash Flow(35.94M)(45.57M)(23.33M)(20.71M)(22.18M)
Capital Expenditures(2.25M)(4.34M)(281K)(516K)(3.19M)
Acquisitions (Net)(11.71M)0000
Purchases of Investments00000
Sales of Investments00367K00
Other Investing Activities00(1.02M)4K0
Investing Cash Flow(13.96M)(4.34M)(932K)(512K)(3.19M)
Debt Repayment(1.53M)(1.43M)(117K)(201K)(510K)
Common Stock Issued77.99M32.84M13.85M27.81M28.66M
Common Stock Repurchased(239K)0000
Dividends Paid00000
Other Financing Activities2.15M(483K)(427K)(1.8M)(74K)
Financing Cash Flow78.36M35.81M12.19M20.43M28.07M
Effect of Forex Changes0000973K
Net Change in Cash28.46M(14.1M)(12.07M)(796K)3.68M
Free Cash Flow(38.19M)(49.91M)(23.61M)(21.23M)(25.37M)

Insight Molecular Diagnostics Inc.

NASDAQ:IMDX

Intrinsic Alpha fair value

Locked

Current Price

$1.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.